There has been great engagement in accountable care organizations (ACOs) because ACOs offer a level of coordinated care that patients are looking for, explained Scott Hewitt, vice president, payment strategy and innovation, UnitedHealthcare.
There has been great engagement in accountable care organizations (ACOs) because ACOs offer a level of coordinated care that patients are looking for, explained Scott Hewitt, vice president, payment strategy and innovation, UnitedHealthcare.
Transcript
What success has UnitedHealthcare seen with its Nexus ACO that it expects it to continue growing?
The biggest success factor that we’ve seen with our Nexus product is the engagement and satisfaction of the members that have selected that product. They really feel that their providers care about them. They’re seeing a more coordinated level of care, and I think that’s the biggest selling point for this product—besides the price point for the employer—it’s the results that the members are seeing.
Why is interest in ACOs growing among commercial payers?
From my perspective, the reason interest is growing in ACOs is cause patients are looking for somebody to help coordinate their care. I know as a personal example, my wife several years ago was diagnosed with breast cancer, and she had to coordinate care, or we had to coordinate the care, between the general surgeon who removed the lump between the plastic surgeon between her oncologist. It was us serving as that go-between for all these different providers making sure that tests were done making sure that results got from one physician to another.
Whereas with an ACO, if that ACO is truly performing at its optimal capabilities, they’re going to coordinate that care for the member, they’re going to make them member feel supported, which I think employers are looking for when employers are trying to decide: where do we want our members to get their care? Where do we want our members to experience care? They’re coming to payers like UnitedHealthcare that offer just such an experience.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Mental Health Awareness: Transforming Workplace Support and Engagement
May 20th 2025Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More